Medical Advocates

HIV Infection/Disease
 
Facial Lipoatrophy Treatment
 
General Reports
Surgery
Injection Therapy
Ultrasound

Growth Hormone




 


 

HIV Facial Lipoatrophy   Main New/Newsworthy Home Page  

Last Update:
 
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports

       

          Journal Papers, Abstracts, and Commentaries

 
FULL TEXT ARTICLE
The Effect of Strength and Endurance Training on Insulin Sensitivity and Fat Distribution in HIV-Infected
Patients with Lipodystrophy.

Carey D, Liew S, Emery S.
|
AIDS Rev. 2008 Apr-Jun;10(2):116-24.|
Abstract
 
Restorative Interventions for HIV Facial Lipoatrophy.
Carey D, Liew S, Emery S.

AIDS Rev.
2008 Apr-Jun;10(2):116-24.
Abstract
 
HIV-associated Facial Lipoatrophy – Review of Current Therapy Options.
Bechara FG, Sand M, Potthoff A, et al 

Eur J Med Res.
2008 Mar 31;13(3):93-9
.
Abstract
 
Long-term psychometric outcomes of facial lipoatrophy therapy: forty-eight-week observational,
nonrandomized study.

Orlando G, Guaraldi G, De Fazio D, et al
AIDS Patient Care STDS. 2007 Nov;21(11):833-42.
Abstract
 
Approaches to Treatment of HIV Facial Lipoatrophy.
Jones D
Skin Therapy Lett. 2005 Nov;10(9):5-7.
Abstract
 
Management options for facial lipoatrophy.
Cofrancesco J Jr, Brown T, Martins CR.
AIDS Read. 2004 Dec;14(12):639-40, 645-50.
Abstract
 

         Conference Reports, Abstracts, and Posters
 

  Psychological assessment of HIV-infected patients with facial lipoatrophy
before and after reparatory treatment

CR Fumaz, JA Muñoz-Moreno, M J Ferrer, et al
(15IAC)
Abstract

Surgery

       

         News
 
  FDA Approves Radiesse for HIV-Associated Facial Lipidatrophy
US FDA
December 23, 2006
News Release

         Journal Papers, Abstracts, and Commentaries

 
Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy,
Thiéry G, Coulet O, Adam S, Guyot L  .
Rev Stomatol Chir Maxillofac. 2008 Mar 27
Abstract
 
Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and
submalar silicone implants.
Mori A, Lo Russo G, Agostini T, et al 

J Plast Reconstr Aesthet Surg
. 2006;59(11):1209-16.
Abstract
 
Facial atrophy in HIV-related fat redistribution syndrome: a plastic surgical perspective on
treatment options and a look to the future.
Abood A, Ong J, Withey S, et al
Int J STD AIDS. 2006 Apr;17(4):217-20.
Abstract
 
Lasting treatment of facial HIV and non HIV lipoatrophies through the use of SAM Gore
Texmalar implants and polyacrylamide hydrogel filler Eutrophill About 90 consecutive cases.
Mole B
Ann Chir Plast Esthet.
2006 Mar 6;
Abstract
 
Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat
tissue transplantation.
Guaraldi G, De Fazio D, Orlando G,et al
Clin Infect Dis. 2005 Jan 15;40(2):e13-5.
Abstract
 
The use of custom-designed midfacial and submalar implants in the treatment
of facial wasting syndrome.
Binder WJ, Bloom DC. et al
Arch Facial Plast Surg. 2004 Nov-Dec;6(6):394-7
Abstract

Treatment of human immunodeficiency virus-associated lipodystrophy with
dermafat graft transfer to the malar area.
Strauch B, Baum T, Robbins N.
Plast Reconstr Surg. 2004 Jan;113(1):363-70; discussion 371-
Abstract
 
Facial Atrophy in HIV-Related Fat Redistribution Syndrome: Anatomic Evaluation and
Surgical Reconstructio
n.
Talmor M, Hoffman LA, LaTrenta GS. Entrez PubMed
Ann Plast Surg
2002 Jul;49(1):11-7

Abstract


Ultrasound

       

              Journal Papers, Abstracts, and Commentaries
 
  Facial lipoatrophy and the place of ultrasound.
Ascher B, Katz P
Dermatol Surg. 2006 May;32(5):698-708.
Abstract

Growth Hormone

       

              Journal Papers, Abstracts, and Commentaries
 
  FULL TEXT PDF ARTICLE
Effectiveness of Subcutaneous Growth Hormone in HIV-1 Patients with Moderate to Severe
Facial Lipoatrophy.
Honda M, Yogi A, Ishizuka N, et al

Intern Med
. 2007;46(7):359-62.

Paper


HIV Lipoatrophy Main Page   Main New/Newsworthy Home Page  

Facial Lipoatrophy Treatment